Natural and Synthetic Cannabinoids: What They Are and How They Might Be Used as Medicine | Research

The takeaway

A review of patents from 2003-2007 cataloged methods for isolating, purifying, and synthesizing cannabinoids and their potential therapeutic applications beyond the FDA-approved uses of dronabinol.

Read this if you want to understand how cannabinoid medicines were being developed in the late 2000s.

Dronabinol was FDA-approved in 1985 and 1992; patent activity showed expanding therapeutic interest

What the researchers found

This review covered the landscape of naturally occurring cannabinoids (phytocannabinoids) and their synthetic analogs, focusing on patents filed between 2003 and 2007.

The review noted that while psychotropic effects of cannabis are mainly attributed to THC, cannabinoids also affect the cardiovascular, immune, and endocrine systems through interactions with CB1 and CB2 receptors.

The FDA had approved synthetic THC (dronabinol/Marinol) in 1985 for chemotherapy-related nausea and in 1992 as an appetite stimulant for AIDS patients. The patent literature from 2003-2007 showed expanded research interest in isolation methods, purification techniques, chemical synthesis routes, and new therapeutic applications.

Why it matters

This review captured the state of cannabinoid pharmaceutical development at a pivotal moment, documenting the expanding commercial and research interest in cannabis-derived medicines.

The numbers in context

Marinol (synthetic THC) was FDA-approved in 1985 for chemotherapy nausea and in 1992 for AIDS-related appetite stimulation. Patent review covered 2003-2007.

How the study worked

Patent review covering methods for cannabis compound isolation, chromatographic purification, synthesis, and therapeutic applications described in patents from 2003 to 2007.

What this study cannot tell us

Patent reviews describe what companies and researchers claim, not what has been clinically validated. Many patented compounds and methods never reach clinical use.

How to read the evidence

Patent review providing a landscape overview rather than clinical evidence. Patents describe potential applications, not proven treatments.

When this study was published

Published in 2009. The cannabinoid pharmaceutical landscape has changed dramatically since then, with CBD (Epidiolex) receiving FDA approval in 2018 and numerous other products in development.

The bigger picture

The patent landscape in 2003-2007 foreshadowed the expansion of cannabinoid-based pharmaceuticals that would follow, including the eventual FDA approval of CBD (Epidiolex) in 2018.

Questions still open

Which of the patented therapeutic applications would eventually be validated in clinical trials? How would the regulatory landscape for cannabinoid medicines evolve?

Common questions

What is the difference between natural and synthetic cannabinoids?

Natural cannabinoids (phytocannabinoids) come from the cannabis plant. Synthetic cannabinoids are created in laboratories to mimic or modify the structure and effects of natural compounds, allowing for standardized dosing and potentially improved therapeutic properties.

Why was there so much patent activity around cannabinoids?

The therapeutic potential of cannabinoids was increasingly recognized, but challenges with plant-derived products (variability, legal issues) drove interest in synthesis and purification methods that could produce pharmaceutical-grade compounds.

Read the original research

Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications.

Recent patents on CNS drug discovery, 4(2), 112-36

View on PubMed ↗

Citation

Galal, Ahmed M; Slade, Desmond; Gul, Waseem; El-Alfy, Abir T; Ferreira, Daneel; Elsohly, Mahmoud A. (2009). Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications.. Recent patents on CNS drug discovery, 4(2), 112-36.